<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119466">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065570</url>
  </required_header>
  <id_info>
    <org_study_id>M14-115</org_study_id>
    <secondary_id>2013-001746-33</secondary_id>
    <nct_id>NCT02065570</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regimens in Subjects With Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of two adalimumab induction regimens in
      subjects with moderately to severely active Crohn's disease and evidence of mucosal
      ulceration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of subject who achieve clinical remission</measure>
    <time_frame>At Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical remission will be scored using Crohn's Disease Activity Index (CDAI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who achieve endoscopic improvement</measure>
    <time_frame>At Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Endoscopic improvement will be scored using Simplified Endoscopic Score for Crohn's Disease (SES CD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve clinical remission</measure>
    <time_frame>At Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical remission will be scored using Crohn's Disease Activity Index (CDAI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who discontinued corticosteroid use and achieved clinical remission</measure>
    <time_frame>At Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical remission will be scored using Crohn's Disease Activity Index (CDAI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of subjects with clinical response</measure>
    <time_frame>From Week 4 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical response will be scored measuring for a decrease in Crohn's Disease Activity Index (CDAI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with endoscopic response</measure>
    <time_frame>At Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Endoscopic improvement will be scored using Simplified Endoscopic Score for Crohn's Disease (SES CD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Bowel disease Questionnaire (IBDQ)</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects are randomized to receive a higher induction regimen of adalimumab.  After the induction regimen is provided, subjects in this arm will receive blinded adalimumab until Week 12.  No placebo arm is planned.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects are randomized to receive a standard induction regimen of adalimumab.  After the induction regimen is provided, subjects in this arm will receive blinded adalimumab until Week 12.  No placebo arm is planned.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Crohn's disease (CD) for at least 90 days, confirmed by endoscopy during
             the Screening Period.

          2. Active CD with a Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450 despite
             treatment with oral corticosteroids and/or immunosuppressants.

          3. Mucosal ulceration on endoscopy.

        Exclusion Criteria:

          1. Subject with ulcerative colitis or indeterminate colitis.

          2. Subject who has had surgical bowel resections in the past 6 months or is planning
             resection.

          3. Subjects with an ostomy or ileoanal pouch.

          4. Subject with bowel stricture or abdominal or peri-anal abcess.

          5. Subject who has short bowel syndrome.

          6. Chronic recurring infections or active Tuberculosis (TB).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Majin  Castillo, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dawn M Gustafson, BS</last_name>
    <phone>847-938-3918</phone>
    <email>dawn.gustafson@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tonee  Puetz, BS</last_name>
    <phone>847-938-6541</phone>
    <email>tonee.puetz@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119037</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119037</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119056</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119056</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119033</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119033</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119042</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119042</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119076</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119076</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119034</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119034</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119040</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265-3726</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119040</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119035</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119035</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119041</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119041</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119052</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119052</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125517</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125517</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119068</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119068</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119050</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119050</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125500</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125500</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119048</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119048</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119036</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119036</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119081</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119081</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>February 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
